NEW YORK, Jan. 21, 2015 /PRNewswire/ -- IntelliCell
BioSciences, Inc. ("IntelliCell" or the "Company")
(OTCQB: SVFC), a regenerative medicine company utilizing adult
autologous stromal vascular fraction cells (SVFCs) derived from the
blood vessels found in adipose tissue, announced today an agreement
for the development of a new closed processing system (the
"System") for its cellular therapy manufacturing with Hielscher
Ultrasonics. Under the agreement, Hielscher Ultrasonics will
provide system design and engineering development for ultrasonic
cavitation manufacturing, and IntelliCell Biosciences will use this
system in its commercial application of its stromal vascular
fraction cellular product, "SVFC."
Logo - http://photos.prnewswire.com/prnh/20150121/170577LOGO
According to Dr. Steven Victor,
CEO, "We are pleased to be partnering with Hielscher Ultrasonics
and Tom Hielscher on the development
of a new technology specifically designed to meet the needs of
manufacturing in our cellular laboratory. By combining Hielscher's
more than 20 years of process development and manufacturing
experience with ultrasonic cavitation and Intellicell's experience
in manufacturing SVFCs, we hope to produce a system that is
patentable and makes the manufacturing process more
streamline."
Thomas Hielscher states,
"Hielscher Ultrasonics (www.hielscher.com) is the world's premier
supplier of high performance, high quality ultrasonic devices.
Hielscher Ultrasonics seeks to continually improve its products and
services in order to fulfill their customers' needs. The permanent
striving for improvement was the initiating step to develop an
optimized ultrasonic reactor for IntelliCell's stem cell
preparation."
In order to separate the stem cells and other beneficial cell
types from the fat tissue, the harvested tissue is treated
ultrasonically. The ultrasound cavitation technology can be
adjusted exactly to the required intensity to break the tissue so
that the cells are released for separation, but mildly enough to
prevent the stem cells from damage.
To improve the ultrasonic cavitation technique, Hielscher
developed for IntelliCell a unique ultrasonic reactor, which allows
the sonication in a sterile, contamination-free environment.
About IntelliCell Biosciences
IntelliCell is a pioneering regenerative medicine company
focused on the expanding regenerative medical markets using adult
autologous stromal vascular fraction cells (SVFCs) derived from the
blood vessels in the adult adipose tissue. IntelliCell BioSciences
has developed its own patented technology and protocol to separate
adult autologous vascular cells from adipose tissue without the use
of enzymes. IntelliCell will also be seeking to develop
technology-licensing agreements with technology developers,
universities, and international business entities.
About Hielscher Ultrasonics
Hielscher Ultrasonics is a family owned business,
located in Teltow near Berlin
(Germany). The main emphasis of
its activities is the conception, development and production of
ultrasonic devices for the use
in laboratory and industrial applications.
Technological innovations together with the realization of new
ultrasound based processes substantiated the company growth and its
market acceptance. Today, ultrasonic devices made by Hielscher
Ultrasonics are being used in laboratories and production plants on
all continents across the world. Hielscher Ultrasonics integrates
the ultrasonic devices into complex ultrasonic systems, such
as wire cleaning systems, too. The systems are produced to
meet the customer's requirements in terms of power, extended range
of accessories and steady state proof equipment
(www.hielscher.com).
Forward-Looking Statements
Certain statements set forth in this press release constitute
"forward-looking statements." Forward-looking statements include,
without limitation, any statement that may predict, forecast,
indicate, or imply future results, performance or achievements, and
may contain the words "estimate," "project," "intend," "forecast,"
"anticipate," "plan," "planning," "expect," "believe," "will
likely," "will reach," "will change," "will soon," "should,"
"could," "would," "may," "can" or words or expressions of similar
meaning. Such statements are not guarantees of future performance
and are subject to risks and uncertainties that could cause the
company's actual results and financial position to differ
materially from those included within the forward-looking
statements. Forward-looking statements involve risks and
uncertainties, including those relating to the Company's ability to
grow its business. Actual results may differ materially from the
results predicted and reported results should not be considered as
an indication of future performance. The potential risks and
uncertainties include, among others, the Company's limited
operating history, the limited financial resources, domestic or
global economic conditions, activities of competitors and the
presence of new or additional competition, and changes in Federal
or State laws. More information about the potential factors that
could affect the Company's business and financial results is
included in the Company's filings, available via the United States
Securities and Exchange Commission.
Contact:
IntelliCell BioSciences, Inc.
Investor Relations
Anna Rhodes
arhodes@intellicellbiosciencesinc.com
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/intellicell-biosciences-announces-collaboration-to-develop-closed-processing-system-for-cell-therapy-manufacturing-300023732.html
SOURCE IntelliCell BioSciences, Inc.